Beam Therapeutics (BEAM) Total Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Liabilities data on file, last reported at $316.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $316.4 million, down 7.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $316.4 million (down 7.98% YoY), and the FY2025 annual result was $242.8 million, down 34.42% from the prior year.
• Total Liabilities climbed to $316.4 million in Q1 2026 per BEAM's latest filing, from $242.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $635.8 million in Q3 2022 and troughed at $242.8 million in Q4 2025.
• A 5-year average of $458.0 million and a median of $446.3 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 130.54% in 2022, then tumbled 34.42% in 2025.
• A 5-year view of Total Liabilities shows it stood at $608.2 million in 2022, then dropped by 21.35% to $478.4 million in 2023, then declined by 22.6% to $370.3 million in 2024, then plunged by 34.42% to $242.8 million in 2025, then soared by 30.29% to $316.4 million in 2026.
• Business Quant data shows BEAM's Total Liabilities at $316.4 million in Q1 2026, $242.8 million in Q4 2025, and $345.1 million in Q3 2025.